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Abstract: Background: Malaria is one of the infectious diseases of greatest interest to the scientific
community and of greatest concern to international health authorities. Traditionally, the focus has
been on Plasmodium falciparum, the parasite that causes the most severe form of the disease in Africa.
However, in the last twenty years, the Plasmodium vivax parasite, responsible for a large number of
cases in Latin America, the Middle East, South and Southeast Asia, the Horn of Africa, and Oceania,
has also generated enormous interest due, among other things, to the published evidence that it can
cause severe malaria. Methods: In this paper, the international scientific publication on malaria and
P. vivax has been analyzed using the Scopus database to try to define global trends in this field of
study. Results: It has been shown that events such as the emergence of resistance to certain drugs can
break a trend. The important role of non-malaria-endemic countries such as the USA or Switzerland
in malaria research is also evident. Conclusions: International cooperation will be essential for the
eradication of the disease. Moreover, in this sense, the general vision given by the bibliometric
analysis of malaria caused by P. vivax is fundamental to paint the picture regarding the current
situation and encourage international cooperation and control efforts.
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1. Introduction
Malaria is a disease that has affected the human population since ancient times. Today, it remains
one of the infectious diseases with the highest morbidity and mortality rates, with 219 million estimated
cases occurred worldwide in 2017, according to WHO, and half a million people dying each year
worldwide, many of them children under five [1]. Because of this, a series of international programs
have been initiated that aim to reduce and eradicate malaria, such as malERA, a research agenda for
malaria elimination and eradication [2]. Human malaria can be caused by different species of the
Plasmodium parasite. P. falciparum and P. vivax are the most important, with more than 95% of the
cases diagnosed in the world, but there are others such as P. malariae, P. knowlesi, P. ovale wallikeri, and
P. ovale curtisi [3].
P. falciparum is the most severe form of the disease in Africa, where more than 90 percent of all
malaria cases occur. For this reason, this is the best-characterized species [4]. However, in recent years,
the infections caused by P. vivax are increasing in significance because of evidence for severe malaria
P. vivax infection [5]. In addition, P. vivax has recently received a large amount of attention, as it is the
species with the largest geographical distribution, being reported fundamentally in Latin America, the
Int. J. Environ. Res. Public Health 2019, 16, 1928; doi:10.3390/ijerph16111928 www.mdpi.com/journal/ijerph
Int. J. Environ. Res. Public Health 2019, 16, 1928 2 of 11
Middle East, South and Southeast Asia, the Horn of Africa and Oceania [6]. This attention received by
P. vivax is not only scientific, as illustrated by the increase in the number of published articles on this
subject, but has also increased interest at the health level, trying to improve the diagnosis of malaria by
these species or the specific treatments. The last factor that makes P. vivax a parasite of growing interest
is its very hard elimination, with a high number of symptomatic relapses in malaria patients [7].
The malaria parasite is transmitted by a female Anopheles mosquito, inoculating sporozoites into
the human host [8]. The sporozoites reach human liver cells, where they transform to give rise to
another form called the merozoite. The merozoite reaches the erythrocytes, through the bloodstream,
and multiples to produce new merozoites. Some of the merozoites released after the breakage of the
erythrocytes are transformed into gametocytes. If the Anopheles mosquito bites an infected individual,
then this is how the merozoites re-enter it. Inside the mosquito, in its midgut, sexual reproduction
takes place, generating zygotes and developing into oocysts. These, as they grow and break, release
sporozoites that invade the mosquito’s salivary glands. The parasite will then in the proper form to
infect a new individual [9]. A fundamental difference in the life cycle of P. vivax is that it can successfully
finish its development cycle in the mosquito at lower temperatures and faster than P. falciparum.
The complexity of the parasite’s life cycle, its great genetic variability, and the numerous
mechanisms it can develop to avoid the host’s immune response, make it very difficult to find a vaccine
to suppress human malaria [10,11]. In addition, the biology of P. vivax, as opposed to P. falciparum,
makes it harder to control and eliminate and is the main reason for the higher vectorial capacity of
P. vivax. Other reasons are related to the presence of hypnozoites (latent hepatic forms), which lead
to multiple relapses and low parasites densities, which in turn makes diagnosis difficult and delays
treatments [12]. On the other hand, there are no suitable experimental models for the analysis of a
hypothetical vaccine. Despite this, finding a vaccine to eradicate malaria caused by P. vivax has become
a fundamental objective for the WHO and the scientific communities around the world.
Bibliometric analyses provide fundamental scientific tools allowing for objective quantification of
a scientific fact. These show the level of current knowledge in a scientific field by the compilation of
data obtained from bibliographic databases. Bibliometrics facilitate comprehension and elaborates a
real image of the research activity. In this study, the analysis of the international scientific publication
on malaria and P. vivax has been raised to establish worldwide trends. It is essential for defining the
research lines in malaria and creating synergies in order to achieve the WHO objective of eradicating
malaria [13].
2. Materials and Methods
The evolution of the electronic age has led to the development of numerous scientific databases
on the World Wide Web, which offer search facilities on a particular issue. Among them, some allow
the opportunity to analyze citations from published works. The main scientific databases covering
medical terms are PubMed, Scopus, Web of Science, and Google Scholar. PubMed focuses essentially
on medicine and biomedical sciences, while Scopus, Web of Science, and Google Scholar cover most
scientific fields. Usually, bibliometric studies are based on the keywords indexed by the published
works. The main differences between these databases are PubMed (no limit), Scopus (30), Web of
Science (15), and Google Scholar (no limit). However, in indexed journals and conference proceedings,
there is usually a limit of about 6 keywords per published work so the limit of 15 is considered
adequate for bibliometric works. However, PubMed’s search function, which is designed to search
for medical documents, are exceptional and offer a service that other search engines do not. In this
database, the search results can only be sorted by general characteristics such as publication date or
author, and therefore, this is not very useful to get an overview of a topic [14]. Nowadays, mainly Web
of Knowledge and Scopus allow large-scale downloads of bibliographic information from indexed
publications and so most of the worldwide bibliometric works are based on one of these two databases.
Scopus is the database that indexes the largest number of publications and conference proceedings
when compared to the other three databases mentioned. Elsevier’s Scopus database is currently the
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largest abstract and citation database of peer-reviewed literature, and although another database,
the Web of Science (WoS), is also available, it lists fewer titles whereas Scopus lists 84% of WoS titles
compared to only 54% of Scopus tiles listed by WoS [15,16].
Scopus is usually considered the largest abstract and citation database of peer-reviewed scientific
literature in the world. It contains more than 35,000 titles belonging to more than 10,000 publishers.
For this reason, in order to analyze who, how, where, and what is being researched in a given scientific
field, the most commonly used option is to use this database. Thus, it is common to find bibliometric
works in many scientific fields using Scopus [17–19]. In short, Scopus is the most effective search
engine and provides an overview of the subject. For extensive and in-depth research in the area of life
sciences and closely related topics, PubMed should be considered as well [14]. For this reason, Scopus
was the database of choice for this analysis.
In this work, a full search of the Elsevier Scopus database was conducted using TITLE-ABS-KEY
(malaria and vivax) as the search query. This resulted in 11,166 documents being obtained between 1916
and 2018, the last full year from Scopus database. It should be noted that varying the search criteria, or
subsequent modifications of Scopus, can give significantly different results. That keywords entered by
the author or publisher may not strictly conform to the subject matter of the articles should also be
considered. Notwithstanding the previous, Scopus is considered a valid option for this type of analysis.
In keyword analysis, terms with identical meanings were grouped together (e.g., Plasmodium vivax and
P. vivax), and terms that do not contribute to this analysis were discarded (e.g., article). The aspects
that have been studied are the progression in the number of publications per year, the distribution
of publications by institutions and by country, and the keywords (Figure 1). For the detection of
scientific communities, understood as the set of nodes connected to each other in a complex network,
the software tool VOSviewer [20] (http://www.vosviewer.com/) was used. This software has been used
to create graphs in which each institution is represented by a node and the connections between two
nodes represent the collaboration between the two institutions represented.
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Figure 1. Methodology for searching the different analyses.
3. Results and Discussion
3.1. Progression of Scientific Output
The search returned 11,166 documents. Figure 2 shows the evolution trend of the number of
documents on Plasmodium vivax and malaria since the first article was published. As shown in Figure 2,
the first article published on this is dated in 1916 [21]. This early entry in the first article shows the
strong interest that the scientific community has placed on malaria over the years.
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Figure 2. The trend of the number of publications in malaria and Plasmodium vivax, from the
years 1916–2018.
The maximum number of annual publications was obtained in 2014, reaching a value of 646.
The growth in the number of publications presents an exponential pattern, with an R2 coefficient close
to 1. There are two years in which the trend is interrupted, and therefore, the R2 value is not even
higher. These are the years 1946 and 1973. In these years, considering the trend line, the publications
were higher than expected. The reason is that, on the one hand, in 1946, chloroquine was identified as
a first-line blood schizontocide for P. vivax [22]. This led to an increased interest in malaria research
and an increase in the publications. On the other hand, in 1973, there was intensification in the disease
due to two reasons: the reduction in international aid programs from developed countries in the
early 1970s, due to the lack of prospects for eradication; and the international economic crisis of 1973,
which pushed up the price of insecticides. Between the years 2002–2010, the increase in the number
of publications was three times greater than the whole previous period. This could be explained by
the first malaria conference, Vivax Malaria Research: 2002 and Beyond, which took place in Bangkok,
Thailand, 3–8 February 2002. This was a conference devoted entirely to Plasmodium vivax research and
convened by the Multilateral Initiative on Malaria [23]. On the other hand, at the turn of the century,
there was a general increase in funding for malaria control, and initiatives such as Roll Back Malaria,
RBM, Partnership were born. This is a major worldwide platform for coordinated action towards a
malaria-free world and is composed of international researchers, companies, and organizations.
3.2. Publication Distribution by Countries and Institutions
To get an overview of worldwide research on a specific subject, one of the aspects most considered
is the study of publications by countries and institutions [24]. Note that when an article has several
affiliations, the indexation implies that the article is attributed to each of them; therefore, the su of
articles by countries could be greater than the sum of articles obtained with the search term. Figure 3
shows the distribution by country of the scientific publication on malaria and P. vivax. In 159 countries,
at least one article on P. vivax has been published, and 25 countries, with at least 150 publications,
represent 75% of the total. Note that the same article may be signed by authors from different countries.
Figure 4 shows the data on a world map with colors identifying the number of manuscripts that are
published in each country. The United States of America, United Kingdom, and India, top the ranking
with 2528, 1439, and 1383 publications, respectively. To normalize the results, the data have been
referenced to the population of each country, based on the 2018 statistics obtained from the website [25]
(Table 1). In this case, it can be observed that there are 10 countries that publish at least 7 articles per
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million inhabitants. These are (ranked from highest to lowest): Switzerland, Australia, Papua New
Guinea, United Kingdom, Netherlands, Thailand, Belgium, France, United States, and Sri Lanka.
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In relative terms, Switzerland very high scientific output is striking. This can be explained
by two reasons. First, Switzerland must be considered an international power in innovation. It is
no c i cidence that the development f an effective malaria vaccine is taking place i the country.
The pharmaceutical industry is well established in this country, and there are numerous public
and private research and development institutions around this type of industry [26]. On the other
hand, Switzerlan is h me to i ternational age cies and institutions concerned with glob l health
care. The Swiss Agency for Development and Cooperation (SDC), an a ency of the Swiss federal
administration responsible for coordinating cooperation and humanitarian aid activities, and the World
Health Organization, whose headquarters are in Geneva, stand out in this regard.
Finally, Table 1 also reflects the relative wealth of each country based on the value of GDP per
capita (IMF data). Thus, it can be observed that the 10 countries studied above are divided into two
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groups. Seven high-income countries (Switzerland, Australia, United Kingdom, Netherlands, Belgium,
France, and United States), with more than 40,000 GDP per inhabitant, and three low-income countries
(Papua New Guinea, Thailand, and Sri Lanka), with less than 7000. The motivations in one or the other
case are different. While in the former, the interest is purely scientific, for the latter it is a question of
survival. In these three countries, malaria is an endemic disease, although in terms of survival, there is
very little malaria in Thailand, and Sri Lanka has eliminated all malaria.
Table 1. Leading countries in terms of scientific research and publication in terms of population and
wealth cited.
Country Publications (N) Population (P)(Mill. of Inhabitants) N/P GDP Per Capita
United States 2528 329,093 7682 62,332
UK 1439 66,959 21,491 41,951
India 1383 1,368,738 1010 1965
Thailand 948 69,306 13,678 6984
Australia 773 25,089 30,812 56,920
Brazil 718 212,393 3381 8988
France 559 65,481 8537 42,684
Switzerland 427 8608 49,605 82,365
China 353 1,420,062 249 9476
Colombia 321 49,850 6439 6580
Japan 318 126,855 2507 39,975
Indonesia 315 269,536 1169 3729
Spain 299 46,441 6438 30,942
South Korea 295 51,339 5746 32,256
Germany 270 82,439 3275 48,872
Netherlands 256 17,133 14,942 53,114
Italy 215 59,217 3631 35,226
Pakistan 206 204,596 1007 1486
Papua New Guinea 205 8587 23,873 3028
Malaysia 198 32,454 6101 11,247
Ethiopia 192 110,136 1743 781
Iran 171 82,821 2065 5059
Canada 162 37,280 4345 46,513
Sri Lanka 158 21,019 7517 4425
Belgium 153 11,563 13,232 48,603
Figure 5 shows the 13 institutions with at least 180 publications on malaria and P. vivax. Of these,
four are from USA (Centers for Disease Control and Prevention, National Institutes of Health in
Bethesda, National Institute of Allergy and Infectious Diseases, and Armed Forces Research Institute
of Medical Sciences known as AFRIMS), three are from the UK (the University of Oxford, Nuffield
Department of Clinical Medicine, and London School of Hygiene and Tropical Medicine), two are
from Thailand (Mahidol University and Shoklo Malaria Research Unit), two are Brazilian (Fundacao
Oswaldo Cruz and Universidade de Sao Paulo), and one is Indian (National Institute of Malaria
Research of India). Note that there may be several affiliations within the same institution but the
database considers them separately respecting the decision of the authors.
As mentioned above, these five countries along with Australia, are the most relevant in scientific
publications on this topic. In addition, it is surprising that among these, there is also an institution
from Papua New Guinea. This is the Papua New Guinea Institute of Medical Research, also known as
PNGIMR, that has the support of the World Health Organization (WHO). Figure 6 shows a distribution
by communities of the main institutions. It can be observed that most institutions are grouped into a
cluster whose central element is the faculty of tropical medicine of the Mahidol University (Thailand).
Each line of union between the nodes represents the relationships established between the institutions.
Thus, the relations are quite complex, and that they are observed not only between the different
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elements of this large cluster but also with the other institutions of the two additional minority clusters.
The two smaller clusters are made up of the Papua New Guinea Institute of Medical Research and the
Swiss Tropical and Public Health Institute, in one, and the Medicines for Malaria Venture (MMV) in
the other.
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3.3. Keyword Analysis
In the analysis of the keywords, if one of them does not contribute anything to the study then it
must be liminated, e.g., “article.” In the second place, all terms that refer o the sam concept must
be grouped together, e.g., “Plasmodium vivax” and “P. vivax.” Figure 7 sh ws, using a word cloud,
that the 32 keywords are in more than 1000 publications on mala ia and P. vivax. In Figure 7, the
relativ size of each wo d is directly proportional to the umber of times the keyword is present in the
analyzed documents. As expected, Plasmodium vivax, human, and malaria, with 9826, 9428, and 8572,
respectively, stand out.
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Among the 32 keywords with more than 1000 presences in the analyzed articles are two drugs,
chloroqui e and primaquine, present in 2395 and 1682 documents, respectively. Furthermore, 11 other
keywords related to drugs are amo g the 160 most used keywords. These are ranked in order of
their importance: quinine, mefloquine, artemisinin, artesunate, pyrimethamine, doxycycline, fansi ar
(actually, the trade name for sulfadoxine/pyrimethamine), artemether lus benflu etol, sulfadoxi e,
proguanil, and amodiaquine. Figure 8 shows that since 1946, the evolution of malaria a d P. vivax
research in relation to the different drugs. As already mentioned, the most important drug as keyword
is chloroquine. Although considering only the last 5 years, the relative importance of primaquine is
similar. This is because the WHO indications are that, in areas where chloroquine maintains its efficacy,
this must be the drug used against malaria caused by P. vivax [27]. On the other hand, primaquine has
been shown to be highly effective in acting against hypnozoites, which are the predominant latent forms
in P. vivax. Furthermore, until recently, it was the only approved hypnozoiticide. For these reasons, to
avoid relapses caused by it, the administration of primaquine is appropriate although there are threats
from incomplete compliance with standards and the development of tolerance, although the real
problem in the supply of this drug is its potential toxicity due to the deficiency, in patients, of the enzyme
G6PD [28]. Figure 8 also shows the relative importance of different drugs at any given time. For example,
mefloquine had a relative maximum in 2004 and how, subsequently, it has been losing relevance due to
its scarce further use. On the contrary, artemisinin—and its derivative artesunate—has a fundamental
importance in recent years, being the most effective drug against all forms of multidrug-resistant
P. falciparum [29]. Other drugs such as fansidar (sulfadoxine/pyrimethamine) or proguanil have
practically no importance in recent publications on malaria and P. vivax, highlighting the trend in the
use of these in the treatment of the disease.
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Figure 8. Time progression of antimalarial drugs in the fight against malaria caused by P. vivax.
Also, it can be seen that the five species of Plasmodium that have been shown to cause malaria
in humans (P. vivax, P. falciparum, P. malariae, P. ovale, and P. knowlesi) are among the 100 most used
keywords. Finally, five countries are also present among the most important keywords: India, Thailand,
Brazil, China, and Papua New Guinea. These are countries where malaria caused by P. vivax is endemic
and they are at the focus of many efforts by the international scientific community to eliminate malaria.
4. Conclusions
Malaria is still one of the world’s major health problems today; both for its extent and for the
priority consideration it has received from public and private organizations concerned with human
health. For thi reason, malaria is a topic that is increasingly published in scientific journals with impact
factors. Moreover, within this theme, malaria caused by P. vivax is currently receiving special interest.
The present study has shown that the growth in the number of publications is exponentially curved,
demonstrating the normous i teres that P. viv x causes in the international scientific community.
This trend is only interrupted by two mom nts in istory when interest in malaria has broken the
norm. Thus, it becomes clear h w bibliomet ic analysis of a given ubject allows fu damental fac s or
mo ents to be identified. I this specific case, i is the discovery of a drug, chloroquine, which proved
to be useful in the fig t against malaria, and the re ound in the number f malaria ca es in the early
1970s due to the relaxati n of the alert level in the international scientific community.
On th ot er hand, the most important countries in terms of scientific publication have be n
identified. In global terms, the USA, UK, and India stand out abov the rest. However, when a more
exhaustive analysis is carried out, and both the population and the wealth of the country are considered,
it is observ d t at there are other countries of greate relativ i p rtance. Thus, Switzerland has been
found to be the count y that devotes the most relative effort to th fight against malaria. This is no
coincidence. This country is a biotech ological benchmark and is hom to many internati nal public
and private bodies that have been working to liminate malaria for decades. The identification of
countries such as Switzerland hig lights the importance of combining technological, scientific, and
politic l effort of publi and private initiatives in the fig t against th disease. This uni n of efforts is
evidenced by the study of the r lationships between the most outstanding institutions an scientists in
the field of malaria and P. vivax. In most cases, there are collaborations that dilute the borders between
rich countries that are d v ting efforts to fight mal ria, such as the UK, and countries where the disease
is a real public health problem, such as Thailand.
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Bibliometric studies not only give an overview of the current state of a scientific issue but can
help to understand policy decisions and shape future scientific research. For this reason, an analysis
of the keywords has been carried out allowing us to identify the main sectors in which the greatest
efforts are being focused on research on malaria and P. vivax. Of these, studies on antimalarials stand
out. The elements that define the lines of international economic investment and objectives in research
projects are the progression of trends, the recommendations of the WHO, the updating of studies on
the effectiveness of drugs, and the existence of resistance to them. It is important to have a general
view of the subject in order to focus on the strategies that are still valid and to open up new promising
lines of research.
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